Raymond James & Associates
MTNB icon

Raymond James & Associates’s Matinas BioPharma MTNB Stock Holding History

Raymond James & Associates’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-29
Closed -$18K – 4144
2022
Q1 		$18K Buy
29
+11
+61% +$6.07K ﹤0.01% 4019
2021
Q4 		$14K Buy
+18
New +$14.4K ﹤0.01% 4055
2019
Q4 		– Sell
-23
Closed -$11K – 3718
2019
Q3 		$11K Buy
23
+6
+35% +$3.25K ﹤0.01% 3559
2019
Q2 		$11K Buy
+17
New +$12.3K ﹤0.01% 3582
2017
Q2 		– Sell
-47
Closed -$98K – 3406
2017
Q1 		$98K Buy
+47
New +$115K ﹤0.01% 3072

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.48B AUM 34.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arkadios Wealth Advisors
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

Raymond James & Associates's MTNB Position: Q2 2022 in Review

Raymond James & Associates sold out of Matinas BioPharma (MTNB) in Q2 2022, closing a stake of 29 shares — an estimated $18K sold.

Raymond James & Associates first reported a position in MTNB in Q1 2017 and held it in 5 quarters. The position peaked at $98K in Q1 2017. 49 funds tracked by Wall St. Rank hold MTNB as of Q2 2022.

  • Raymond James & Associates reported no remaining Matinas BioPharma position as of Q2 2022 after selling out during the quarter.
  • Raymond James & Associates sold 29 Matinas BioPharma shares in Q2 2022, an estimated $18K.
  • Raymond James & Associates first reported a position in Matinas BioPharma in Q1 2017 and held it in 5 quarters.
  • Raymond James & Associates's Matinas BioPharma position peaked at $98K in Q1 2017.
  • 49 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.